<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020072</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067694</org_study_id>
    <secondary_id>NCI-00-C-0068</secondary_id>
    <nct_id>NCT00020072</nct_id>
    <nct_alias>NCT00004546</nct_alias>
  </id_info>
  <brief_title>Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells</brief_title>
  <official_title>Gene Expression Analysis in Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Analyzing genes that are present in cancer cells may be useful in developing&#xD;
      better methods to detect, predict, and treat cutaneous T-cell lymphoma.&#xD;
&#xD;
      PURPOSE: Clinical trial to study genes that are present in cutaneous T-cell lymphoma cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify gene expression patterns in malignant T cells that can be used to diagnose&#xD;
           cutaneous T-cell lymphoma.&#xD;
&#xD;
        -  Determine the patterns of gene expression that distinguish normal skin-homing T cells&#xD;
           from malignant T cells.&#xD;
&#xD;
      OUTLINE: Patients are stratified by disease (Sezary syndrome vs mycosis fungoides) and prior&#xD;
      treatment (yes vs no).&#xD;
&#xD;
      All patients receive a physical examination, and a medical history is taken. Patients with&#xD;
      Sezary syndrome undergo leukapheresis. Patients with plaque/tumor stage mycosis fungoides&#xD;
      undergo skin biopsy of involved skin. Malignant T cells from blood or skin are then isolated&#xD;
      and patterns of gene expression in the malignant T cells are compared to those in normal&#xD;
      skin-homing T cells from healthy donors using a &quot;gene chip&quot; (Lymphochip).&#xD;
&#xD;
      Patients are followed annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients (20 per disease stratum) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven mycosis fungoides with 2 or more plaques or tumors greater than&#xD;
             1 cm in size OR&#xD;
&#xD;
          -  Immunologically proven Sezary syndrome with all of the following:&#xD;
&#xD;
               -  Erythroderma&#xD;
&#xD;
               -  Lymphadenopathy&#xD;
&#xD;
               -  T-cell receptor variable beta chain clonality greater than 10% of total&#xD;
                  lymphocytes by flow cytometry OR&#xD;
&#xD;
               -  CD4+CD7- T-cell fraction that represents greater than 10% of CD4+ T cells&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 85&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  HIV-1 and HTLV-1 negative&#xD;
&#xD;
          -  No prior intravenous drug use&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 months since prior systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 2 months since prior electron beam radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 2 weeks since prior topical therapy&#xD;
&#xD;
          -  At least 2 months since prior photopheresis&#xD;
&#xD;
          -  At least 2 months since prior psoralen ultraviolet light (PUVA) or ultraviolet B (UVB)&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam T. Hwang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Dermatology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hwang ST, Fitzhugh DJ. Aberrant expression of adhesion molecules by SÃ©zary cells: functional consequences under physiologic shear stress conditions. J Invest Dermatol. 2001 Mar;116(3):466-70.</citation>
    <PMID>11231324</PMID>
  </results_reference>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

